Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis

On July 22, 2025 Caris Life Sciences (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and further reinforcing its leadership in precision oncology (Press release, Caris Life Sciences, JUL 22, 2025, View Source [SID1234654473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a champion of scientific collaboration, Caris appreciated the opportunity to validate a recent study published in the New England Journal of Medicine, which brought attention to the clinical challenge of TI-CH—blood-derived mutations that infiltrate tumor tissue and are often misinterpreted as tumor-specific mutations. These misinterpretations can lead to inappropriate treatment decisions and poorer patient outcomes.

"The ability to validate important studies shows how collaboration between Caris scientists and a Caris Precision Oncology Alliance member can quickly respond to and confirm new discoveries, enhancing clinically meaningful insights for oncologists and their patients," said David Spetzler, MS, PhD, MBA, President of Caris. "This precision ensures that treatment decisions are based on true tumor biology, ultimately leading to better outcomes for patients."

Caris built on the findings from the study and analyzed 3,255 matched tumor–blood NGS samples from its extensive real-world clinico-genomic database of over 500,000 samples. The study focused on patients with late-stage cancer and confirmed TI-CH is prevalent across solid tumors, with the highest incidence in non-small cell lung cancer (NSCLC) – approximately 1 in every 4 patients (23%). Patients with TI-CH have worse outcomes, with a 30% higher risk of death compared to patients without TI-CH.

"Clonal hematopoietic mutations play a critical role in the precision oncology puzzle," said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. "Understanding their role in treatment response will lead to improved patient outcomes."